Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.58 |
| ▸ | MAPK13 | O15264 | 11/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.58 |
| ▸ | CDK8 | P49336 | 2/20 | 0.55 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | CCNC | P24863 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1013047 | 0.93 | MAPK13 (0.54) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL1013230 | 0.92 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL378957 | 0.92 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL15492471 | 0.92 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL1783390 | 0.90 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL15492491 | 0.89 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL1064616 | 0.88 | MAPK13 (0.56) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL17920842 | 0.88 | BRAF (0.45) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL15492502 | 0.86 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL1012616 | 0.86 | MAPK13 (0.66) | MAPK14MAPK13MAPK12MAPK11JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2017-10-19 | — | — | US | disclosed |
| US-9730937-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160199375-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2016-07-14 | — | — | US | disclosed |
| US-9320739-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150246042-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2015-09-03 | — | — | US | disclosed |
| US-8969587-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140045868-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160199375-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | MAPK14 145/4885MAPK13 117/4885MAPK12 139/4885 |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | MAPK14 145/4885MAPK13 117/4885MAPK12 139/4885 |
| US-20150246042-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | MAPK14 145/4885MAPK13 117/4885MAPK12 139/4885 |
| US-20140045868-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | MAPK14 145/4885MAPK13 117/4885MAPK12 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.